Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder

ConditionsPTSD - Post Traumatic Stress Disorder PTSD PTSD Symptoms PTSD, Post Traumatic Stress Disorder

Trial statusNot yet recruiting

Trial phasePhase 2, Phase 3

Trial typeInterventional

Biological sexAll

Age18+

SponsorCOMPASS Pathways

About this trial

The Redefine Study (COMP202) is testing COMP360 to see if it may reduce post-traumatic stress disorder (PTSD) symptoms when administered alongside monitoring and support from a trained study team. COMP360 is a lab-made form of the naturally occurring chemical compound psilocybin.

Eligibility criteria

Qualifiers

18 years or older

Diagnosed with PTSD at least 6 months ago

Disqualifiers

None

Trial design

Treatments tested in this trial

COMP360 psilocybin

Treatment groups

300 Participants

are divided into 3 treatment groups

Locations

This trial has no locations

Sponsors and collaborators

COMPASS Pathways

Lead sponsor

Source ClinicalTrials.gov